APS
MCID: ANT006
MIFTS: 60

Antiphospholipid Syndrome (APS)

Categories: Blood diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Antiphospholipid Syndrome

MalaCards integrated aliases for Antiphospholipid Syndrome:

Name: Antiphospholipid Syndrome 12 76 53 25 37 55 44 15 73
Antiphospholipid Antibody Syndrome 12 53 25 63
Hughes Syndrome 53 25 54
Familial Antiphospholipid Syndrome 53 73
Acromegaloid Facial Appearance Syndrome 73
Lupus Anticoagulant, Familial 53
Anti-Phospholipid Syndrome 25
Aps 53

Classifications:



External Ids:

Disease Ontology 12 DOID:2988
ICD10 33 D68.61
MeSH 44 D016736
NCIt 50 C61283
SNOMED-CT 68 19267009 26843008
KEGG 37 H01697

Summaries for Antiphospholipid Syndrome

NINDS : 54 Antiphospholipid syndrome (APS) is an autoimmune disorder caused when antibodies -- immune system cells that fight off bacteria and viruses -- mistakenly attack healthy body tissues and organs.  In APS, specific antibodies activate the inner lining of blood vessels, which leads to the formation of blood clots in arteries or veins.  APS is sometimes called “sticky blood syndrome,” because of the increased tendency to form blood clots in the veins and arteries.  The symptoms of APS are due to the abnormal blood clotting.  Clots can develop in the veins of the legs and lungs, or in the placenta of pregnant women.  One of the most serious complications of APS occurs when a clot forms in the brain and causes a stroke.  Other neurological symptoms include chronic headaches, dementia (similar to the dementia of Alzheimer’s disease), and seizures.  Infrequently, individuals will develop chorea (a movement disorder in which the body and limbs writhe uncontrollably), cognitive dysfunction (such as poor memory), transverse myelitis, depression or psychosis, optic neuropathy, or sudden hearing loss.  In pregnant women, clots in the placenta can cause miscarriages.  APS is diagnosed by the presence of a positive antiphospholipid antibody and either a history of blood clots in an artery or vein or a history of multiple miscarriages or other pregnancy problems.  Some individuals will have a characteristic lacy, net-like red rash called livedo reticularis over their wrists and knees. 

MalaCards based summary : Antiphospholipid Syndrome, also known as antiphospholipid antibody syndrome, is related to catastrophic antiphospholipid syndrome and thrombocytopenia, and has symptoms including unspecified visual loss An important gene associated with Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Enoxaparin and Heparin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 An autoimmune hypersensitivity disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin).

Genetics Home Reference : 25 Antiphospholipid syndrome is a disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. This clotting tendency is known as thrombophilia. In antiphospholipid syndrome, the thromboses can develop in nearly any blood vessel in the body, but most frequently occur in the vessels of the lower limbs. If a blood clot forms in the vessels in the brain, blood flow is impaired and can lead to stroke. Antiphospholipid syndrome is an autoimmune disorder. Autoimmune disorders occur when the immune system attacks the body's own tissues and organs.

NIH Rare Diseases : 53 Antiphospholipid syndrome (APS) is an autoimmune disorder. Signs and symptoms vary, but may include blood clots, miscarriage, rash, chronic headaches, dementia, and seizures. APS occurs when your body's immune system makes antibodies that attack phospholipids. Phospholipids are a type of fat found in all living cells, including blood cells and the lining of blood vessels. Most cases of APS occur in people with no family history of the disorder, however there are rare cases of APS clustering in a family. A widely accepted explanation for APS is that it is caused by a combination of genemutations (making one more susceptible to APS) and an environmental exposure (such as to a virus). Currently there is not a cure for APS. The goal of treatment is to prevent blood clots from forming and to keep existing clots from getting larger.

PubMed Health : 63 About antiphospholipid antibody syndrome: Antiphospholipid (AN-te-fos-fo-LIP-id) antibody syndrome (APS) is an autoimmune disorder. Autoimmune disorders occur if the body's immune system makes antibodies that attack and damage tissues or cells. Antibodies are a type of protein. They usually help defend the body against infections. In APS, however, the body makes antibodies that mistakenly attack phospholipids—a type of fat. Phospholipids are found in all living cells and cell membranes, including blood cells and the lining of blood vessels.When antibodies attack phospholipids, cells are damaged. This damage causes blood clots to form in the body's arteries and veins. (These are the vessels that carry blood to your heart and body.)Usually, blood clotting is a normal bodily process. Blood clots help seal small cuts or breaks on blood vessel walls. This prevents you from losing too much blood. In APS, however, too much blood clotting can block blood flow and damage the body's organs.

Wikipedia : 76 Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune,... more...

Related Diseases for Antiphospholipid Syndrome

Diseases in the Antiphospholipid Syndrome family:

Antiphospholipid Syndrome, Familial

Diseases related to Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 509)
# Related Disease Score Top Affiliating Genes
1 catastrophic antiphospholipid syndrome 33.7 ADAMTS13 APOH CD40LG F3 F5 MTHFR
2 thrombocytopenia 30.7 ADAMTS13 APOH F3
3 connective tissue disease 30.3 ADAMTS13 APOH CD40LG
4 heparin-induced thrombocytopenia 30.1 CD40LG F10 F3 SERPINC1
5 sudden sensorineural hearing loss 30.1 APOH F2 F5 MTHFR
6 papilledema 30.1 APOH F2
7 endocarditis 30.1 APOH F2 PLAT SERPINC1 VCAM1
8 may-thurner syndrome 30.0 APOH F5
9 pulmonary hypertension 29.9 F3 PLAT THBD VWF
10 budd-chiari syndrome 29.9 APOH F2 F3 F5 MTHFR SERPINC1
11 prothrombin deficiency 29.9 F2 F3
12 hepatic infarction 29.8 APOH F2 F3 MTHFR SERPINC1
13 cerebral sinovenous thrombosis 29.8 APOH F2 F3 F5
14 eclampsia 29.8 F2 MTHFR SERPINC1 THBD
15 polycythemia vera 29.8 F5 SELP THBD
16 coronary thrombosis 29.8 F3 PLAT SERPINC1 VWF
17 thrombocytosis 29.8 F2 F3 SELP SERPINC1
18 carotid artery occlusion 29.7 APOH F5 THBD
19 retinal artery occlusion 29.7 APOH F2 F5 MTHFR SERPINC1
20 acute myocardial infarction 29.7 F3 PLAT SELP SERPINC1 VWF
21 sneddon syndrome 29.7 APOH F2 SERPINC1
22 purpura fulminans 29.7 F2 F3 SERPINC1
23 carotid artery dissection 29.7 ADAMTS13 MTHFR PLAT
24 nonarteritic anterior ischemic optic neuropathy 29.7 F2 F5 MTHFR SERPINC1
25 coronary artery anomaly 29.7 F2 F5 PLAT SELP
26 arteritic anterior ischemic optic neuropathy 29.7 F2 F5 MTHFR
27 systemic lupus erythematosus 29.6 ADAMTS13 ANXA5 APOH CD40LG F2 F3
28 protein s deficiency 29.6 APOH F2 F3 F5 MTHFR SERPINC1
29 ischemic colitis 29.6 APOH F2 F5 SERPINC1
30 branch retinal artery occlusion 29.6 APOH F2 F3 MTHFR SERPINC1
31 placenta disease 29.6 ANXA5 APOH F3 F5 MTHFR SERPINC1
32 livedoid vasculitis 29.6 APOH F2 MTHFR SERPINC1
33 retinal vein occlusion 29.6 APOH F2 F5 MTHFR SERPINC1
34 ischemic optic neuropathy 29.6 APOH F2 F5 MTHFR SERPINC1
35 purpura 29.5 ADAMTS13 APOH F2 F3 SERPINC1 THBD
36 raynaud phenomenon 29.5 APOH THBD VWF
37 central retinal vein occlusion 29.4 APOH F2 F5 MTHFR SERPINC1
38 osteonecrosis 29.4 F2 MTHFR SERPINC1
39 severe pre-eclampsia 29.4 APOH F5 SERPINC1 VCAM1
40 thrombophlebitis 29.4 APOH F2 F5 MTHFR PLAT SERPINC1
41 patent foramen ovale 29.4 APOH F2 F5 MTHFR PLAT SERPINC1
42 carotid artery thrombosis 29.4 F10 F3 PLAT SELP
43 thrombosis 29.4 ADAMTS13 APOH F10 F2 F3 F5
44 portal vein thrombosis 29.4 APOH F2 F5 MTHFR SELP SERPINC1
45 thrombophilia 29.4 APOH F2 F3 F5 MTHFR SERPINC1
46 sagittal sinus thrombosis 29.4 F2 F3 F5 SERPINC1
47 antithrombin iii deficiency 29.4 APOH F10 F2 F5 MTHFR SERPINC1
48 angina pectoris 29.4 PLAT SERPINC1 VWF
49 hemolytic uremic syndrome, atypical 1 29.3 ADAMTS13 THBD VWF
50 hellp syndrome 29.3 ADAMTS13 APOH F2 F3 F5 MTHFR

Graphical network of the top 20 diseases related to Antiphospholipid Syndrome:



Diseases related to Antiphospholipid Syndrome

Symptoms & Phenotypes for Antiphospholipid Syndrome

UMLS symptoms related to Antiphospholipid Syndrome:


unspecified visual loss

MGI Mouse Phenotypes related to Antiphospholipid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ADAMTS13 APOH CD40LG F10 F2 F3
2 cardiovascular system MP:0005385 10.26 CD40LG F10 F2 F3 F5 PLAT
3 hematopoietic system MP:0005397 10.23 ADAMTS13 ANXA5 CD40LG F2 F3 PLAT
4 immune system MP:0005387 10.18 ADAMTS13 ANXA5 CD40LG F2 F3 PLAT
5 mortality/aging MP:0010768 10.13 ADAMTS13 APOH CD40LG F10 F2 F3
6 integument MP:0010771 10.02 CD40LG F2 F3 F5 MTHFR PLAT
7 nervous system MP:0003631 9.85 CD40LG F2 F3 F5 MTHFR PLAT
8 liver/biliary system MP:0005370 9.8 F5 MTHFR SELE SELP SERPINC1 THBD
9 reproductive system MP:0005389 9.56 CD40LG F10 F2 MTHFR PLAT SERPINC1
10 vision/eye MP:0005391 9.17 ADAMTS13 F3 MTHFR PLAT SELE SELP

Drugs & Therapeutics for Antiphospholipid Syndrome

PubMedHealth treatment related to Antiphospholipid Syndrome: 63

Antiphospholipid antibody syndrome (APS) has no cure. However, medicines can help prevent complications. The goals of treatment are to prevent blood clots from forming and keep existing clots from getting larger.You may have APS and another autoimmune disorder, such as lupus. If so, it's important to control that condition as well. When the other condition is controlled, APS may cause fewer problems.Research is ongoing for new ways to treat APS.

Drugs for Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enoxaparin Approved Phase 4,Phase 2,Early Phase 1,Not Applicable 9005-49-6 772
2
Heparin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable 9005-49-6 772 46507594
3
Dalteparin Approved Phase 4,Phase 2,Early Phase 1,Not Applicable 9005-49-6
4
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
5
leucovorin Approved Phase 4 58-05-9 6006 143
6
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
7
Acetaminophen Approved Phase 4,Phase 1,Not Applicable 103-90-2 1983
8
Apixaban Approved Phase 4 503612-47-3 10182969
9
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 56-45-1 5951
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Vaccines Phase 4,Phase 2
13 Antibodies, Antiphospholipid Phase 4,Phase 3,Phase 2,Not Applicable
14 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
15 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 calcium heparin Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable
18 Heparin, Low-Molecular-Weight Phase 4,Phase 2,Early Phase 1,Not Applicable
19 Fibrinolytic Agents Phase 4,Phase 2,Early Phase 1,Not Applicable
20 Antithrombins Phase 4,Phase 3,Phase 2,Not Applicable
21
protease inhibitors Phase 4,Phase 3,Phase 2
22 Antithrombin III Phase 4,Phase 3,Phase 2,Not Applicable
23 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2
24 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
25 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2
26 Vitamins Phase 4
27 Vitamin B9 Phase 4
28 Vitamin B Complex Phase 4
29 Folate Phase 4
30 Hematinics Phase 4
31 Trace Elements Phase 4
32 Micronutrients Phase 4
33 Antipyretics Phase 4,Phase 2,Not Applicable,Early Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable,Early Phase 1
35 Analgesics Phase 4,Phase 2,Not Applicable,Early Phase 1
36 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable,Early Phase 1
37
Hydroxychloroquine Approved Phase 3,Phase 2,Not Applicable 118-42-3 3652
38
Acenocoumarol Approved, Investigational Phase 3 152-72-7 9052 54676537
39 tannic acid Approved Phase 2, Phase 3,Phase 1
40
Benzocaine Approved, Investigational Phase 2, Phase 3,Phase 1 94-09-7, 1994-09-7 2337
41 Antiprotozoal Agents Phase 3,Phase 2,Not Applicable
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
44 Antiparasitic Agents Phase 3,Phase 2,Not Applicable
45 Antimalarials Phase 3,Phase 2,Not Applicable
46 Autoantibodies Phase 3,Phase 1
47 Antivitamins K Phase 3
48
Aspirin Approved, Vet_approved Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable 50-78-2 2244
49
rituximab Approved Phase 2 174722-31-7 10201696
50
Fluvastatin Approved Phase 2 93957-54-1 1548972

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Rivaroxaban for Antiphospholipid Antibody Syndrome Completed NCT02116036 Phase 4 Rivaroxaban
3 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
4 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
5 Drug Interaction Between Paracetamol and Warfarin Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
6 Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome Recruiting NCT02295475 Phase 4 Apixaban;Warfarin
7 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
8 Rivaroxaban for Patients With Antiphospholipid Syndrome Completed NCT02926170 Phase 3 Rivaroxaban;acenocumarol
9 Hydroxychloroquine for Prevention of Recurrent Miscarriage. Recruiting NCT03165136 Phase 3 Hydroxychloroquine;Placebo
10 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Not yet recruiting NCT03540810 Phase 3 Hydroxychloroquine;Placebo
11 RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome Not yet recruiting NCT03684564 Phase 2, Phase 3 Rivaroxaban;Warfarin
12 Rivaroxaban in Thrombotic Antiphospholipid Syndrome Terminated NCT02157272 Phase 3 Experimental: Rivaroxaban
13 Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients Terminated NCT01784523 Phase 3 Hydroxychloroquine
14 Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome Unknown status NCT02595346 Phase 2 Hydroxychloroquine;placebo
15 Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss Unknown status NCT00180778 Phase 1, Phase 2 Low dose steroids
16 A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome Completed NCT00537290 Phase 2 Rituximab
17 Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients Completed NCT00674297 Phase 2 Fluvastatin
18 Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome Completed NCT01051778 Phase 2 enoxaparin 40mg plus low dose aspirin;Heparin calcium5,000 U twice daily plus low dose aspirin
19 Aspirin in Asymmetrically Intrauterine Growth Completed NCT03038607 Phase 2 Aspirin
20 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
21 IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy Recruiting NCT03152058 Phase 2 Certolizumab Pegol
22 Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome Active, not recruiting NCT01029587 Phase 2 Eculizumab
23 Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome Terminated NCT02128269 Phase 2
24 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
25 Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
26 Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome Withdrawn NCT00278616 Phase 1
27 Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome Unknown status NCT01661439 low molecular weight heparin (enoxeparine)
28 Antiphospholipid Antibodies and Early Severe Preeclampsia. Unknown status NCT01538121
29 Antiphospholipid Antibodies and Fetal Growth Restriction Unknown status NCT01538134
30 Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies. Unknown status NCT00180817
31 Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients Unknown status NCT02218476 Not Applicable CoQ10;Placebo
32 The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome Unknown status NCT01818505
33 Ocular Findings in Women With Primary Antiphospholipid Syndrome Completed NCT03459508
34 Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome Completed NCT01660061
35 Antiphospholipid Syndrome Collaborative Registry (APSCORE) Completed NCT00076713
36 Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin Completed NCT00878137
37 The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations Completed NCT02855047
38 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
39 CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients Completed NCT02139072
40 Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome Completed NCT00010400 Not Applicable Cyclophosphamide;filgrastim
41 Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System) Completed NCT02892565 Not Applicable
42 CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen Completed NCT01762891 Not Applicable Celecoxib;Acetaminophen;Rofecoxib;placebo
43 Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) Completed NCT01475149
44 Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy Completed NCT00721591
45 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
46 Clinical Significance of Antiphospholipid Antibodies in Healthy Subjects Completed NCT02803645 Not Applicable
47 Pharmacogenetics of Warfarin in Puerto Ricans. Completed NCT01318057
48 Extra Corporeal Membrane Oxygenation in the Acute Respiratory Distress Syndrome: Utility of a Biomarker to Assess the Membrane Efficiency in Improving Oxygenation Completed NCT02879344 Not Applicable
49 Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter Recruiting NCT03600636 Not Applicable
50 Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study Recruiting NCT00616317

Search NIH Clinical Center for Antiphospholipid Syndrome

Cochrane evidence based reviews: antiphospholipid syndrome

Genetic Tests for Antiphospholipid Syndrome

Anatomical Context for Antiphospholipid Syndrome

MalaCards organs/tissues related to Antiphospholipid Syndrome:

41
Brain, Testes, Endothelial, Heart, Lung, Placenta, Bone

Publications for Antiphospholipid Syndrome

Articles related to Antiphospholipid Syndrome:

(show top 50) (show all 2596)
# Title Authors Year
1
Dyspnea and Edema in a Woman With Antiphospholipid Syndrome. ( 29955809 )
2018
2
Antiphospholipid Syndrome Complicating Pneumococcal Meningitis. ( 29845960 )
2018
3
Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. ( 29895622 )
2018
4
Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome. ( 29948348 )
2018
5
Catastrophic antiphospholipid syndrome and pregnancy. Clinical report. ( 29284338 )
2018
6
Catastrophic antiphospholipid syndrome and pregnancy. ( 29179957 )
2018
7
Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. ( 29977578 )
2018
8
Anticoagulation in a patient with antiphospholipid syndrome and a mechanical heart valve: a case study. ( 29939846 )
2018
9
Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. ( 29402471 )
2018
10
A case of extreme weight loss due to mesenteric ischemia and antiphospholipid syndrome. ( 29881563 )
2018
11
Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. ( 29395258 )
2018
12
Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? ( 29891914 )
2018
13
Difficulties in the treatment of recurring diffuse alveolar hemorrhage accompanying primary antiphospholipid syndrome: a case report and literature review. ( 29960279 )
2018
14
The antiphospholipid syndrome and its 'non-criteria' manifestations. ( 29449418 )
2018
15
Decreased hippocampal cell proliferation in mice with experimental antiphospholipid syndrome. ( 29936552 )
2018
16
Reversible Parkinsonism and Multiple Cerebral Infarctions after Pulmonary Endarterectomy in a Patient with Antiphospholipid Syndrome. ( 29321405 )
2018
17
Necrotising scleritis, keratitis and uveitis in primary antiphospholipid syndrome. ( 29764818 )
2018
18
Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease. ( 29339317 )
2018
19
Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome. ( 29429123 )
2018
20
Immunoglobulins from sera of antiphospholipid syndrome patients are internalized in the HTR-8/SVneo cell line and cytotrophoblast in culture. ( 29960807 )
2018
21
Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? ( 29885541 )
2018
22
Manuscript title: Cardiac and neurological involvement in Antiphospholipid syndrome: a case of a 47-year-old woman with nonbacterial thrombotic endocarditis and cognitive impairment. ( 29936322 )
2018
23
Oromandibular chorea in antiphospholipid syndrome. ( 29305492 )
2018
24
Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. ( 29904380 )
2018
25
Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses. ( 29355608 )
2018
26
The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. ( 29779928 )
2018
27
Assessment of diagnostic methods for the detection of anticardiolipin and anti-I^eta<sub>2</sub> glycoprotein I antibodies in patients under routine evaluation for antiphospholipid syndrome. ( 29883633 )
2018
28
Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. ( 29635999 )
2018
29
Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis. ( 29879927 )
2018
30
Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. ( 29478799 )
2018
31
Tolerogenic I^2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. ( 29894515 )
2018
32
Rare Presentation of Catastrophic Antiphospholipid Syndrome with Myocarditis in Post-partum Period: Case Report and Review of Literature. ( 29391679 )
2018
33
Antiphospholipid syndrome. ( 29368699 )
2018
34
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. ( 29978552 )
2018
35
Thrombocytopenia in high-risk patients with antiphospholipid syndrome. ( 29316193 )
2018
36
Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome. ( 29940673 )
2018
37
A Patient With Remote Heparin-Induced Thrombocytopenia and Antiphospholipid Syndrome Requiring Cardiopulmonary Bypass: Do Current Guidelines Apply? ( 29871549 )
2018
38
Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. ( 29338587 )
2018
39
Antiphospholipid syndrome. ( 29321639 )
2018
40
Antiphospholipid syndrome, &amp;quot;the best prophet of the future&amp;quot;. ( 29385876 )
2018
41
Clinical Report of Probable Catastrophic Antiphospholipid Syndrome in Pregnancy. ( 29808136 )
2018
42
Immunomodulation in the Treatment of Refractory Catastrophic Antiphospholipid Syndrome. ( 29805821 )
2018
43
Immunoproteomic identification of anti-C9 autoimmune antibody in patients with seronegative obstetric antiphospholipid syndrome. ( 29894483 )
2018
44
Acute adrenal insufficiency due to adrenal hemorrhage complicating colorectal surgery: Report of two cases and correlation with the antiphospholipid antibody syndrome. ( 30145500 )
2018
45
The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. ( 30253290 )
2018
46
Diagnosis and Management of the Antiphospholipid Syndrome. ( 30257161 )
2018
47
Spontaneous Retroperitoneal Bleeding in a Patient with Primary Antiphospholipid Syndrome on Aspirin. ( 30258659 )
2018
48
Diagnosis and Management of the Antiphospholipid Syndrome. ( 30260601 )
2018
49
Diagnosis and Management of the Antiphospholipid Syndrome. ( 30260602 )
2018
50
Diagnosis and Management of the Antiphospholipid Syndrome. ( 30260603 )
2018

Variations for Antiphospholipid Syndrome

Copy number variations for Antiphospholipid Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160790 22 16300000 24300000 Deletion Hughes'' syndrome

Expression for Antiphospholipid Syndrome

Search GEO for disease gene expression data for Antiphospholipid Syndrome.

Pathways for Antiphospholipid Syndrome

Pathways related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 ANXA5 APOH F10 F2 F3 F5
2
Show member pathways
12.57 F10 F2 F3 F5 SERPINC1 THBD
3
Show member pathways
12.01 F2 SELE SELP THBD
4 11.89 CD40LG SELE SELP VCAM1
5 11.85 PLAT SELE THBD VCAM1
6
Show member pathways
11.76 F10 F2 F3 F5 PLAT SERPINC1
7 11.62 F3 SELE THBD VCAM1
8
Show member pathways
11.45 CD40LG SELE VCAM1
9 11.37 F10 F2 F3 F5 PLAT SERPINC1
10 11.25 CD40LG SELE SELP VCAM1
11 10.67 F10 F2

GO Terms for Antiphospholipid Syndrome

Cellular components related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 ADAMTS13 APOH CD40LG F3 PLAT THBD
2 external side of plasma membrane GO:0009897 9.77 ANXA5 CD40LG F2 SELP VCAM1
3 endoplasmic reticulum lumen GO:0005788 9.72 ADAMTS13 F10 F2 F5 SERPINC1
4 extracellular region GO:0005576 9.7 ADAMTS13 ANXA5 APOH CD40LG F10 F2
5 collagen-containing extracellular matrix GO:0062023 9.63 ANXA5 APOH F3 PLAT SERPINC1 VWF
6 extracellular space GO:0005615 9.44 ADAMTS13 APOH CD40LG F10 F2 F3
7 platelet alpha granule GO:0031091 9.43 F5 VWF
8 intrinsic component of external side of plasma membrane GO:0031233 9.4 F10 F3

Biological processes related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.81 SELE SELP THBD VCAM1
2 platelet activation GO:0030168 9.78 ADAMTS13 CD40LG F2 VWF
3 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.7 SELE SELP VCAM1
4 platelet degranulation GO:0002576 9.65 ANXA5 APOH F5 SELP VWF
5 blood coagulation GO:0007596 9.65 ADAMTS13 ANXA5 F10 F2 F3 F5
6 leukocyte tethering or rolling GO:0050901 9.63 SELE SELP VCAM1
7 blood coagulation, intrinsic pathway GO:0007597 9.61 APOH F2 VWF
8 negative regulation of proteolysis GO:0045861 9.58 F2 PLAT
9 calcium-mediated signaling using intracellular calcium source GO:0035584 9.58 SELP VCAM1
10 negative regulation of blood coagulation GO:0030195 9.58 ANXA5 APOH THBD
11 fibrinolysis GO:0042730 9.57 F2 PLAT
12 positive regulation of blood coagulation GO:0030194 9.56 APOH F2
13 plasminogen activation GO:0031639 9.55 APOH PLAT
14 negative regulation of platelet activation GO:0010544 9.54 F2 THBD
15 regulation of blood coagulation GO:0030193 9.54 APOH F2 SERPINC1
16 negative regulation of fibrinolysis GO:0051918 9.5 APOH F2 THBD
17 blood coagulation, extrinsic pathway GO:0007598 9.49 F10 F3
18 leukocyte cell-cell adhesion GO:0007159 9.46 CD40LG SELE SELP VCAM1
19 hemostasis GO:0007599 9.28 ADAMTS13 ANXA5 F10 F2 F3 F5

Molecular functions related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type peptidase activity GO:0008236 9.65 F10 F2 PLAT
2 integrin binding GO:0005178 9.63 ADAMTS13 VCAM1 VWF
3 calcium ion binding GO:0005509 9.63 ADAMTS13 ANXA5 F10 F2 SELP THBD
4 protease binding GO:0002020 9.58 F3 SERPINC1 VWF
5 serine-type endopeptidase activity GO:0004252 9.56 F10 F2 F3 PLAT
6 oligosaccharide binding GO:0070492 9.37 SELE SELP
7 sialic acid binding GO:0033691 9.32 SELE SELP
8 phospholipid binding GO:0005543 9.26 ANXA5 APOH F10 F3
9 heparin binding GO:0008201 9.02 ANXA5 APOH F2 SELP SERPINC1
10 protein binding GO:0005515 10.28 ADAMTS13 ANXA5 APOH CD40LG F10 F2

Sources for Antiphospholipid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....